www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Companies

Xi'an Janssen plans 10 drug launches in four areas by 2020

By Wang Wen (China Daily) Updated: 2015-10-31 09:50

Xi'an Janssen Pharmaceutical Ltd, Johnson & Johnson Services Inc's largest subsidiary in China, plans to launch more than 10 new medicines in China by 2020.

Kris Sterkens, chairman of Jassen Asia Pacific, said innovation remains its core strategy, and its products will be spread over four main treatment areas: tumors, the autoimmune system, mental health and infectious and metabolic diseases such as hepatitis and diabetes.

The firm's new-product strategy, he said, was being supported by a number of recent findings that showed China has strong demand for medicine targeted at those diseases.

A survey by the Economist Intelligence Unit, a global business intelligence belonging to the Economist Group, for instance, analyzed markets in five countries across Asia Pacific including China, and reached the conclusion that "the region now carries a huge global burden of non-communicable diseases, such as cancer and mental illness".

As many as 85 percent of deaths in China in 2010 were the result of non-communicable diseases, according to the report, with cancer, cardiovascular disease and diabetes topping the list of causes.

"Healthcare systems in Asia Pacific are struggling to manage the rise in non-communicable diseases and the shift to long-term treatment of chronic conditions," said Charles Ross, the survey report's editor.

Following on from those and other findings, Xi'an Janssen will launch a new product for prostate cancer soon, said Sterkens. Research is also being conducted on a diabetes medicine.

Xi'an Janssen has launched 14 major new products in the past five years aimed at treating conditions like human immunodeficiency virus, cancer and mental illness.

Established 30 years ago, it has been a regular investor in China since its launch.

A new $290 million plant in Xi'an will be in operation from 2018, said Cesar Rodriguez, the company's chief.

The new site will have an annual capacity of 280 million medicine packages, which will be sold around the world, said Rodriguez.

Xi'an Janssen is well known in China for over-the-counter drugs such as Domperidone and Daktarin.

Johnson & Johnson combined its OTC business in China last year with Xi'an Janssen, a controversial move at the time with some industry commentators fearing the integration might hurt sales.

Rodriguez insisted the integration, named One China OTC, has achieved strong results, although he refused to detail exact numbers.

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 超级碰碰碰在线观看 | 久草社区视频 | 亚洲精品国产拍拍拍拍拍 | 俄罗斯极品美女毛片免费播放 | 老司机精品影院一区二区三区 | 久久综合精品国产一区二区三区无 | 日本三级韩国三级在线观看a级 | 国产a级特黄的片子视频 | 欧美激情久久久久久久久 | 久久久久国产精品免费 | 久久久精品久久视频只有精品 | 精品久久久视频 | 欧美国产91 | 亚洲一区 中文字幕 久久 | 国产欧美一区二区精品久久久 | 亚洲a级在线观看 | 国产三及 | 明星国产欧美日韩在线观看 | 国产成人v视频在线观看 | 久久一本精品 | chinese情侣真实自拍 | 在线日本视频 | 99热官网 | 国外精品视频在线观看免费 | 欧美人成毛片在线播放 | 日本韩国一级片 | 91色综合久久 | 欧美日韩顶级毛片www免费看 | 成人毛片在线 | 美女被男人桶到嗷嗷叫爽网站 | 国产亚洲欧美一区 | 一级片久久 | 久草视频精品 | 午夜性福| 国产一级大片在线观看 | 成人亚洲精品 | 午夜不卡视频 | 91成人午夜在线精品 | 韩国在线精品福利视频在线观看 | 九月婷婷亚洲综合在线 | 91视频99 |